A highly soft and skin-friendly sanitary napkin and a method for manufacturing the same

Abstract

The present application relates to the field of sanitary products, and provides a high-soft skin-friendly sanitary napkin and a preparation method thereof, which solves the problem that the existing sanitary napkin has poor adhesion effect of bacteriostatic components, cannot specifically inhibit harmful bacteria in the vagina, promote the dominant position of beneficial bacteria in the vagina in the bacterial community, does not have the function of releasing bacteriostatic components under specific conditions, cannot have high-efficiency bacteriostasis while reducing the long-time contact of bacteriostatic components with the skin of the vagina, and has a problem of high cytotoxicity; the sanitary napkin comprises, from top to bottom, a surface layer, a flow guide layer, a core body and a leakage-proof bottom film, the surface layer is modified pure cotton non-woven fabric, and the modified pure cotton non-woven fabric is obtained by rolling and drying after immersing pure cotton non-woven fabric in bacteriostatic component microcapsule mixed solution.

Description

TECHNICAL FIELD

[0001] The present application relates to the field of sanitary products, in particular to a high-softness skin-friendly sanitary napkin and a preparation method thereof. BACKGROUND

[0002] With the rapid development of society, people's living standards are constantly improving, and functional sanitary napkins have gradually been favored by consumers. Menstrual sanitary napkins absorb a large amount of menstrual blood, which is composed of blood and shed necrotic endometrium, containing a variety of bacterial nutrients. In addition, the environment of the sanitary napkin is humid and not breathable, which can easily breed a large number of bacteria. The vaginal environment of women before menstruation is in a weakly acidic environment with a pH value of about 3.8-4.4, and the weakly acidic environment can effectively inhibit the reproduction of bacterial pathogens. During menstruation, the weakly alkaline menstrual blood flows out, disrupting the acid-base balance of the vaginal environment and breaking the natural protective barrier of the vaginal environment, thereby increasing the risk of bacterial vaginal infection. Therefore, it is necessary to increase the antibacterial function of the sanitary napkin. However, current sanitary napkin antibacterial treatment mostly uses broad-spectrum antibacterial ingredients, indiscriminately killing harmful bacteria and beneficial bacteria in the vagina, causing normal flora disorder and breaking the natural protective barrier of the vaginal environment.

[0003] Chinese Patent Application No. 202211523283.9 discloses a preparation method of an antibacterial and breathable sanitary napkin. The prepared surface rapid penetration layer, antibacterial chip, intermediate absorption core layer and leakage-proof bottom layer are cut according to the size and then bonded in order to obtain an antibacterial and breathable sanitary napkin. The antibacterial chip is soaked in a traditional Chinese medicine extract, which includes oregano concentrate 4-10 parts, cinnamon concentrate 3-5 parts, thyme concentrate 6-12 parts, tea leaf concentrate 1-5 parts, and litsea cubeba essential oil 5-8 parts and clove essential oil 4-7 parts. The synergistic effect of several traditional Chinese medicine substances effectively inhibits the breeding and reproduction of microorganisms, and has a protective effect on the skin mucosa, reduces irritation, and avoids skin itching. However, the sanitary napkin does not have the function of specifically inhibiting harmful bacteria in the vagina, and it is difficult to maintain the balance of beneficial bacteria flora. Moreover, the antibacterial ingredients do not have the function of slow release, and the adhesion effect of the antibacterial ingredients on the non-woven fabric material is relatively poor.

[0004] Chinese patent application No. 202410774282.4 discloses a skin care sanitary napkin containing milk fruit essential oil microcapsules. The milk fruit essential oil microcapsules are in the form of hollow spherical balls, and the milk fruit essential oil is distributed in the continuous phase of the wall material. When coming into contact with menstrual blood, the milk fruit essential oil begins to release and slowly releases at body temperature, achieving good repair effect. The beeswax in phase A has good antibacterial effect, and the N-2-hydroxypropyl-3-trimethyl ammonium chloride chitosan also has good antibacterial effect due to the introduction of quaternary ammonium groups. The synergistic effect of the two enhances the antibacterial effect of the sanitary napkin. The N-2-hydroxypropyl-3-trimethyl ammonium chloride chitosan and sodium carboxymethyl cellulose impart good water solubility and biocompatibility to the microcapsules. When the composite film liquid prepared therefrom is sprayed on the non-woven fabric, it exhibits good biocompatibility and enhances the adhesion of the microcapsules on the non-woven fabric material. However, the sanitary napkin does not have the function of specifically inhibiting harmful bacteria and is difficult to maintain the balance of beneficial bacteria. SUMMARY

[0005] Therefore, in order to solve the above problems, the present application provides a high-soft skin-friendly sanitary napkin and a preparation method thereof, which solves the problem of poor adhesion of the antibacterial component of the existing sanitary napkin, cannot specifically inhibit harmful bacteria in the vagina, promote the dominant position of beneficial bacteria in the bacterial community, does not have the function of releasing antibacterial components under specific conditions, cannot simultaneously have high-efficiency antibacterial effect while reducing the long-term contact of the antibacterial component with the vaginal skin, and has a large cytotoxicity problem.

[0006] To achieve the above-mentioned purpose, the present application adopts the following technical solutions:

[0007] A high-soft skin-friendly sanitary napkin, comprising a surface layer, a flow guide layer, a core body and a leakage-proof bottom film arranged in sequence from top to bottom, wherein the surface layer is a modified pure cotton non-woven fabric, which is obtained by impregnating pure cotton non-woven fabric in an antibacterial component microcapsule mixture, rolling and drying; the surface layer comprises pure cotton non-woven fabric and antibacterial component microcapsules adhered to the surface of the pure cotton non-woven fabric, the antibacterial component microcapsules have a three-layer structure, comprising a first composite layer as the outermost layer, a second composite layer as the next outer layer and a third composite layer as the innermost layer; the first composite layer is polydopamine conjugated with polyacrylic acid, the second composite layer is hyaluronic acid modified polylactic acid, and the third composite layer is a mixture of cis-9-unsaturated long-chain fatty acid and oregano essential oil;

[0008] The antibacterial component microcapsule mixture comprises the following raw materials: cis-9-unsaturated long-chain fatty acid, oregano essential oil, hyaluronic acid, polylactic acid, dichloromethane, polyvinyl alcohol, polyacrylic acid, 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide, N-hydroxysuccinimide, dopamine, ammonia water and deionized water.

[0009] Further, the first composite layer is dissolved when contacting the weak alkaline menstrual blood.

[0010] Further, the second composite layer is dissolved when contacting the bacterial extracellular hydrolase.

[0011] Further, the first composite layer is dissolved before the second composite layer.

[0012] Further, the bacteriostatic component microcapsule releases a mixture of cis-9-unsaturated long-chain fatty acids and oregano essential oil when simultaneously contacting the weak alkaline menstrual blood and the hyaluronidase secreted by bacteria.

[0013] A preparation method of a high-softness skin-friendly sanitary napkin, comprising the following preparation steps:

[0014] S1, preparation of a composite bacteriostatic solution: uniformly mix cis-9-unsaturated long-chain fatty acids and oregano essential oil in a weight ratio of 1:1-3 to obtain a composite bacteriostatic solution;

[0015] S2, preparation of a bacteriostatic component microcapsule suspension: take 1-10 parts by weight of hyaluronic acid and 10-30 parts by weight of deionized water, add the hyaluronic acid to the deionized water and stir to dissolve to obtain a hyaluronic acid solution; take 1-10 parts by weight of polylactic acid and add it to the hyaluronic acid solution, stir to dissolve, and form a mixed solution of hyaluronic acid-modified polylactic acid, then treat it by dialysis to obtain a dialysate; take 10-30 parts by weight of the composite bacteriostatic solution and 45-60 parts by weight of dichloromethane and add them to the dialysate to mix uniformly as an oil phase; take 10-30 parts by weight of polyvinyl alcohol and dissolve it in 100-300 parts by weight of deionized water as an aqueous phase, mix the oil phase and the aqueous phase uniformly, and perform water bath reaction for 1-3 h, then perform high-speed shearing treatment to obtain a bacteriostatic component microcapsule suspension;

[0016] S3, preparation of a PD powder: dissolve 15-30 parts by weight of polyacrylic acid in 150-300 parts by weight of deionized water, add 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and N-hydroxysuccinimide as catalysts, mix uniformly, perform ice water bath reaction for 3-4 h, then add dopamine and mix uniformly, stir for 20-24 h, then perform dialysis treatment, and freeze-dry to obtain a PD powder;

[0017] S4, preparation of bacteriostatic component microcapsules: the bacteriostatic component microcapsule suspension obtained in step S2 is dispersed in an ammonia buffer solution to obtain a first mixed solution; the PD powder obtained in step S3 is dissolved in deionized water to obtain a second mixed solution; the second mixed solution is slowly added to the first mixed solution while stirring uniformly, and the stirring is continued for 20-24 h to perform a dopamine self-polymerization reaction to form polydopamine, centrifugal treatment is performed to remove the supernatant, the precipitate is taken and washed with deionized water, vacuum drying is performed, and the bacteriostatic component microcapsules are obtained;

[0018] S5, preparation of modified pure cotton non-woven fabric: the bacteriostatic component microcapsules obtained in step S4 are dissolved in water, the pH is adjusted to 6-6.5 to obtain a bacteriostatic component microcapsule mixed solution, then the pure cotton non-woven fabric is immersed in the bacteriostatic component microcapsule mixed solution, and after rolling, drying is performed to obtain the modified pure cotton non-woven fabric;

[0019] S6, preparation of high-soft skin-friendly sanitary napkin: the modified pure cotton non-woven fabric is used as a surface layer of the sanitary napkin, and the sanitary napkin is compounded according to the structure of surface layer, flow guide layer, core body, and leakage-proof bottom film from top to bottom to obtain the high-soft skin-friendly sanitary napkin.

[0020] Further, the dialysis treatment is performed in a dialysis bag with a molecular weight cut-off of 3000-3500 Da for 4-8 h.

[0021] Further, the water bath reaction is performed in a magnetic stirring water bath kettle, and the water bath temperature is 40-60 DEG C.

[0022] Further, the high-speed shearing treatment is performed in a high-speed shearing homogenizer, and the rotation speed is 10,000-12,000 rpm.

[0023] Further, the centrifugal treatment is performed in a centrifuge, and the rotation speed is 5,000-6,000 r / min for 5-10 min.

[0024] By adopting the foregoing technical solutions, the present application has the following beneficial effects:

[0025] 1. According to the English literature Vaginal Lactobacillus fatty acid response mechanisms reveal a metabolite-targeted strategy for bacterial vaginosis treatment. Zhu, Meilin et al. Cell, Volume 187, Issue 19, 5413-5430.e29. It is indicated that cis-9-unsaturated long-chain fatty acid components can selectively inhibit inert lactobacillus, while promoting beneficial lactobacillus; cis-9-unsaturated long-chain fatty acids can be used as sanitary napkin antibacterial ingredients in combination with oregano essential oil, which can effectively kill harmful bacteria in the vagina in vitro, and promote the dominant position of beneficial bacteria in the bacterial community, maintain the balance of vaginal microecology, and enhance the resistance to harmful bacteria.

[0026] 2. The preparation of pH and bacterial hydrolytic enzyme double-responsive double-shell antibacterial microcapsules, first, the hyaluronic acid (HA) modified polylactic acid (PLA) is used as the wall material to embed the antibacterial ingredients, and the HA-PLA@antibacterial ingredient microcapsule suspension is obtained; then, PAA-DOPA is obtained by conjugating polyacrylic acid (PAA) and dopamine (DOPA); the HA-PLA@antibacterial ingredient microcapsule suspension is dispersed in an ammonia buffer solution to obtain a first mixed solution; the PAA-DOPA powder is dissolved in deionized water to obtain a second mixed solution; then, the second mixed solution is slowly added to the first mixed solution, and the amide reaction occurs between HA and DOPA on the surface of the antibacterial ingredient microcapsule, and the self-polymerization of DOPA occurs under weak alkaline conditions to form polydopamine (PDA), and the PAA-PDA is deposited on the outer shell of the HA-PLA@antibacterial ingredient microcapsule to form the outermost layer of the microcapsule. The reaction conditions of this process are mild and the operation is fast and convenient, and finally the PAA-PDA@HA-PLA@antibacterial ingredient microcapsule is obtained.

[0027] 3. The outermost layer of the antibacterial ingredient microcapsule is PAA-PDA, which dissolves when it contacts weak alkaline menstrual blood; the next outer layer of the antibacterial ingredient microcapsule is HA-PLA, which dissolves when it contacts the menstrual blood and the bacterial extracellular hydrolase and HA, and the antibacterial substance in the inner layer is released; therefore, the antibacterial substance can only be released when the antibacterial ingredient microcapsule contacts weak alkaline menstrual blood and bacterial hyaluronidase at the same time, and the antibacterial effect is high, so the contact time between the antibacterial ingredient and the vaginal skin can be reduced, and the cytotoxicity is reduced. The sanitary napkin prepared by this technical solution has high antibacterial effect while reducing the long-term contact between the antibacterial ingredient and the vaginal skin, and further increases the stability of the antibacterial ingredient on the sanitary napkin. The selected microcapsule materials all have the advantage of high biocompatibility, which is very suitable for use during menstruation.

[0028] 4. The PAA-PDA forms the outermost layer of the microcapsule, and the catechol functional group in the PDA structure forms a hydrogen bond with the hydroxyl group on the surface of the cotton fiber, so that the antibacterial and skin-protecting nanocapsule can be firmly adhered to the pure cotton non-woven fabric without the need to introduce other adhesives, thereby reducing the use of other chemicals, improving the biocompatibility of the pure cotton non-woven fabric, and reducing the risk of allergy and irritation. BRIEF DESCRIPTION OF DRAWINGS

[0029] Figure 1 is a data graph of the cumulative release amount of the antibacterial component under different conditions in Example 4 of the present application;

[0030] Figure 2 is a morphological graph of the effect of the antibacterial component microcapsule solution on L929 cells in Example 7 of the present application. DETAILED DESCRIPTION

[0031] Example 1

[0032] A preparation method of a high-soft and skin-friendly sanitary napkin, comprising the following preparation steps:

[0033] (1) Preparation of a composite antibacterial solution: uniformly mix cis-9-unsaturated long-chain fatty acid and oregano essential oil according to a weight ratio of 1:1 to obtain a composite antibacterial solution;

[0034] (2) Preparation of an antibacterial component microcapsule suspension: take 1 part by weight of hyaluronic acid and 10 parts by weight of deionized water, stir and dissolve the hyaluronic acid in the deionized water to obtain a hyaluronic acid solution; take 1 part by weight of polylactic acid and add it to the hyaluronic acid solution, stir and dissolve to form a mixed solution of hyaluronic acid modified polylactic acid, then perform dialysis treatment in a dialysis bag with a molecular weight cut-off of 3000 Da for 4 hours to obtain a dialysate; take 10 parts by weight of the composite antibacterial solution and 45 parts by weight of dichloromethane and add them to the dialysate to mix uniformly as an oil phase; take 10 parts by weight of polyvinyl alcohol and dissolve it in 100 parts by weight of deionized water as an aqueous phase, mix the oil phase and the aqueous phase uniformly, perform water bath reaction in a magnetic stirring water bath for 1 hour with a water bath temperature of 40℃, and then perform high-speed shearing treatment in a high-speed shearing homogenizer at a speed of 10000 rpm to obtain an antibacterial component microcapsule suspension;

[0035] (3) Preparation of PD powder: 15 parts by weight of polyacrylic acid is dissolved in 150 parts by weight of deionized water, 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide and N-hydroxysuccinimide are added as catalysts, mixed uniformly, reacted in an ice water bath for 3h, then dopamine is added, mixed uniformly, stirred for 20h, then dialysis treatment is carried out in a dialysis bag with a molecular weight cut-off of 3000Da for 4h, freeze-dried to obtain PD powder;

[0036] (4) Preparation of bacteriostatic component microcapsules: the bacteriostatic component microcapsule suspension obtained in step (2) is dispersed in an ammonia buffer solution to obtain a first mixed solution; the PD powder obtained in step (3) is dissolved in deionized water to obtain a second mixed solution; the second mixed solution is slowly added to the first mixed solution while stirring uniformly, and the stirring is continued for 20h to form polydopamine through self-polymerization of dopamine; centrifugal treatment is carried out in a centrifuge at a speed of 5000r / min for 5min, the supernatant is removed, the precipitate is taken and washed with deionized water, and vacuum drying is carried out to obtain bacteriostatic component microcapsules;

[0037] (5) Preparation of modified pure cotton non-woven fabric: the bacteriostatic component microcapsules obtained in step (4) are dissolved in water, the pH is adjusted to 6 to obtain a bacteriostatic component microcapsule mixed solution, then the pure cotton non-woven fabric is immersed in the bacteriostatic component microcapsule mixed solution, rolled and dried to obtain a modified pure cotton non-woven fabric;

[0038] (6) Preparation of high-soft skin-friendly sanitary napkin: the modified pure cotton non-woven fabric is used as the surface layer of the sanitary napkin, and the sanitary napkin is compounded according to the structure of surface layer, flow guide layer, core body, and leakage-proof bottom film from top to bottom to obtain the high-soft skin-friendly sanitary napkin.

[0039] The high-soft skin-friendly sanitary napkin comprises a surface layer, a flow guide layer, a core body, and a leakage-proof bottom film arranged from top to bottom, wherein the surface layer is a modified pure cotton non-woven fabric obtained by rolling and drying the pure cotton non-woven fabric immersed in a bacteriostatic component microcapsule mixed solution; the surface layer comprises a pure cotton non-woven fabric and bacteriostatic component microcapsules adhered to the surface of the pure cotton non-woven fabric, the bacteriostatic component microcapsules have a three-layer structure comprising a first composite layer as the outermost layer, a second composite layer as the next outermost layer, and a third composite layer as the innermost layer; the first composite layer is polyacrylic acid conjugated polydopamine, the second composite layer is hyaluronic acid modified polylactic acid, and the third composite layer is a mixture of cis-9-unsaturated long-chain fatty acid and oregano essential oil;

[0040] The bacteriostatic component microcapsule mixed solution comprises the following raw materials: cis-9-unsaturated long-chain fatty acid, oregano essential oil, hyaluronic acid, polylactic acid, dichloromethane, polyvinyl alcohol, polyacrylic acid, 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide, N-hydroxysuccinimide, dopamine, ammonia water and deionized water.

[0041] The first composite layer is dissolved when contacting weak alkaline menstrual blood, and the second composite layer is dissolved when contacting bacterial extracellular hydrolase, the first composite layer is dissolved earlier than the second composite layer, and the bacteriostatic component microcapsule releases a mixture of cis-9-unsaturated long-chain fatty acid and oregano essential oil when simultaneously contacting weak alkaline menstrual blood and hyaluronidase secreted by bacteria.

[0042] Embodiment 2

[0043] A preparation method of a high-softness skin-friendly sanitary napkin comprises the following preparation steps:

[0044] (1) Preparation of composite bacteriostatic solution: uniformly mix cis-9-unsaturated long-chain fatty acid and oregano essential oil at a weight ratio of 1:2 to obtain a composite bacteriostatic solution;

[0045] (2) Preparation of bacteriostatic component microcapsule suspension: take 5 parts by weight of hyaluronic acid and 20 parts by weight of deionized water, stir and dissolve the hyaluronic acid in the deionized water to obtain a hyaluronic acid solution; take 5 parts by weight of polylactic acid and add it to the hyaluronic acid solution, stir and dissolve to form a mixed solution of hyaluronic acid modified polylactic acid, then perform dialysis treatment in a dialysis bag with a molecular weight cut-off of 3200 Da for 6 hours to obtain a dialysate; take 20 parts by weight of the composite bacteriostatic solution and 50 parts by weight of dichloromethane and mix them uniformly as an oil phase; take 20 parts by weight of polyvinyl alcohol and dissolve it in 200 parts by weight of deionized water as an aqueous phase, mix the oil phase and the aqueous phase uniformly, perform water bath reaction in a magnetic stirring water bath for 2 hours at a water bath temperature of 50°C, and then perform high-speed shearing treatment in a high-speed shearing homogenizer at a speed of 11000 rpm to obtain a bacteriostatic component microcapsule suspension;

[0046] (3) Preparation of PD powder: dissolve 25 parts by weight of polyacrylic acid in 200 parts by weight of deionized water, add 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide and N-hydroxysuccinimide as catalysts, mix uniformly, perform ice water bath reaction for 3.5 hours, then add dopamine and mix uniformly, stir for 22 hours, then perform dialysis treatment in a dialysis bag with a molecular weight cut-off of 3200 Da for 6 hours, and freeze-dry to obtain PD powder;

[0047] (4) Preparation of bacteriostatic component microcapsules: the bacteriostatic component microcapsule suspension obtained in step (2) is dispersed in an ammonia buffer solution to obtain a first mixed solution; the PD powder obtained in step (3) is dissolved in deionized water to obtain a second mixed solution; the second mixed solution is slowly added to the first mixed solution while stirring uniformly, and the stirring is continued for 22 h to perform a self-polymerization reaction of dopamine to form polydopamine, and centrifugal treatment is performed in a centrifuge at a speed of 5500 r / min for 8 min, the supernatant is removed, the precipitate is taken and washed with deionized water, and vacuum drying is performed to obtain bacteriostatic component microcapsules;

[0048] (5) Preparation of modified pure cotton non-woven fabric: the bacteriostatic component microcapsules obtained in step (4) are dissolved in water, the pH is adjusted to 6.2 to obtain a bacteriostatic component microcapsule mixed solution, and then the pure cotton non-woven fabric is immersed in the bacteriostatic component microcapsule mixed solution, rolled, and dried to obtain a modified pure cotton non-woven fabric;

[0049] (6) Preparation of high-soft skin-friendly sanitary napkin: the modified pure cotton non-woven fabric is used as a surface layer of the sanitary napkin, and the sanitary napkin is compounded according to the structure of surface layer, flow guide layer, core body, and leakage-proof bottom film from top to bottom to obtain the high-soft skin-friendly sanitary napkin.

[0050] The high-soft skin-friendly sanitary napkin comprises a surface layer, a flow guide layer, a core body, and a leakage-proof bottom film arranged in sequence from top to bottom, the surface layer is a modified pure cotton non-woven fabric, and the modified pure cotton non-woven fabric is obtained by rolling and drying the pure cotton non-woven fabric immersed in a bacteriostatic component microcapsule mixed solution; the surface layer comprises pure cotton non-woven fabric and bacteriostatic component microcapsules adhered to the surface of the pure cotton non-woven fabric, the bacteriostatic component microcapsules have a three-layer structure comprising a first composite layer as an outermost layer, a second composite layer as a sub-outermost layer, and a third composite layer as an innermost layer; the first composite layer is polydopamine conjugated with polyacrylic acid, the second composite layer is polylactic acid modified with hyaluronic acid, and the third composite layer is a mixture of cis-9-unsaturated long-chain fatty acid and oregano essential oil;

[0051] The bacteriostatic component microcapsule mixed solution comprises cis-9-unsaturated long-chain fatty acid, oregano essential oil, hyaluronic acid, polylactic acid, dichloromethane, polyvinyl alcohol, polyacrylic acid, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, N-hydroxysuccinimide, dopamine, ammonia water, and deionized water.

[0052] The first composite layer dissolves when contacting weak alkaline menstrual blood, the second composite layer dissolves when contacting bacterial extracellular hydrolase, the first composite layer dissolves earlier than the second composite layer, and the bacteriostatic component microcapsules release a mixture of cis-9-unsaturated long-chain fatty acid and oregano essential oil when simultaneously contacting weak alkaline menstrual blood and hyaluronidase secreted by bacteria.

[0053] Example 3

[0054] A preparation method of a high-soft skin-friendly sanitary napkin, comprising the following preparation steps:

[0055] (1) Preparation of composite bacteriostatic solution: according to the weight ratio of cis-9-unsaturated long-chain fatty acid and oregano essential oil being 1:3, the cis-9-unsaturated long-chain fatty acid and the oregano essential oil are uniformly mixed to obtain a composite bacteriostatic solution;

[0056] (2) Preparation of bacteriostatic component microcapsule suspension: 10 parts by weight of hyaluronic acid and 30 parts by weight of deionized water are weighed, the hyaluronic acid is added to the deionized water and stirred to dissolve, to obtain a hyaluronic acid solution; 10 parts by weight of polylactic acid is added to the hyaluronic acid solution and stirred to dissolve, to form a mixed solution of hyaluronic acid modified polylactic acid, which is then subjected to dialysis treatment in a dialysis bag with a molecular weight cut-off of 3500 Da for 8 hours to obtain a dialysate; 30 parts by weight of the composite bacteriostatic solution and 60 parts by weight of dichloromethane are added to the dialysate and uniformly mixed as an oil phase; 30 parts by weight of polyvinyl alcohol is dissolved in 300 parts by weight of deionized water as an aqueous phase, the oil phase and the aqueous phase are uniformly mixed, and water bath reaction is performed in a magnetic stirring water bath for 3 hours at a water bath temperature of 60°C, and then high-speed shearing treatment is performed in a high-speed shearing homogenizer at a speed of 12000 rpm to obtain a bacteriostatic component microcapsule suspension;

[0057] (3) Preparation of PAA-DOPA powder: 30 parts by weight of polyacrylic acid is dissolved in 300 parts by weight of deionized water, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and N-hydroxysuccinimide are added as catalysts, and uniformly mixed, and ice water bath reaction is performed for 4 hours, then dopamine is added and uniformly mixed, and stirred for 24 hours, then dialysis treatment is performed in a dialysis bag with a molecular weight cut-off of 3500 Da for 8 hours, and freeze-drying is performed to obtain PD powder;

[0058] (4) Preparation of bacteriostatic component microcapsule: the bacteriostatic component microcapsule suspension obtained in step (2) is dispersed in an ammonia buffer solution to obtain a first mixed solution; the PD powder obtained in step (3) is dissolved in deionized water to obtain a second mixed solution; the second mixed solution is slowly added to the first mixed solution while stirring uniformly, and stirring is continued for 24 hours to perform a self-polymerization reaction of dopamine to form polydopamine, centrifugal treatment is performed in a centrifuge at a speed of 6000 r / min for 10 minutes, the supernatant is removed, the precipitate is washed with deionized water, and vacuum drying is performed to obtain bacteriostatic component microcapsules;

[0059] (5) Preparation of modified pure cotton non-woven fabric: the bacteriostatic component microcapsule obtained in step (4) is dissolved in water, the pH is adjusted to 6.5 to obtain a bacteriostatic component microcapsule mixture, and then the pure cotton non-woven fabric is immersed in the bacteriostatic component microcapsule mixture, rolled and dried to obtain the modified pure cotton non-woven fabric;

[0060] (6) Preparation of high-soft skin-friendly sanitary napkin: the modified pure cotton non-woven fabric is used as the surface layer of the sanitary napkin, and the structure from top to bottom is surface layer, flow guide layer, core body, and leakage-proof bottom film to obtain the high-soft skin-friendly sanitary napkin.

[0061] The high-soft skin-friendly sanitary napkin comprises a surface layer, a flow guide layer, a core body, and a leakage-proof bottom film arranged from top to bottom, wherein the surface layer is a modified pure cotton non-woven fabric obtained by rolling and drying the pure cotton non-woven fabric immersed in a bacteriostatic component microcapsule mixture; the surface layer comprises pure cotton non-woven fabric and bacteriostatic component microcapsules adhered to the surface of the pure cotton non-woven fabric, the bacteriostatic component microcapsules have a three-layer structure comprising a first composite layer as the outermost layer, a second composite layer as the next outermost layer, and a third composite layer as the innermost layer; the first composite layer is polydopamine conjugated with polyacrylic acid, the second composite layer is hyaluronic acid modified polylactic acid, and the third composite layer is a mixture of cis-9-unsaturated long-chain fatty acid and oregano essential oil.

[0062] The bacteriostatic component microcapsule mixture comprises the following raw materials: cis-9-unsaturated long-chain fatty acid, oregano essential oil, hyaluronic acid, polylactic acid, dichloromethane, polyvinyl alcohol, polyacrylic acid, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, N-hydroxysuccinimide, dopamine, ammonia water, and deionized water.

[0063] The first composite layer dissolves when it contacts weak alkaline menstrual blood, the second composite layer dissolves when it contacts bacterial extracellular hydrolase, the first composite layer dissolves before the second composite layer, and the bacteriostatic component microcapsule releases a mixture of cis-9-unsaturated long-chain fatty acid and oregano essential oil when it simultaneously contacts weak alkaline menstrual blood and hyaluronidase secreted by bacteria.

[0064] Example 4

[0065] As Figure 1To study the response of the release of the bacteriostatic component under the double stimulation of pH and hyaluronidase (HAase), PBS solutions with pH values of 6.0 and 7.4 were prepared, and hyaluronidase solutions with pH values of 6.0 and 7.4 were prepared. The modified pure cotton non-woven fabric obtained in Example 1 was placed in four beakers, 200 mL of PBS solution with pH 6.0, 200 mL of PBS solution with pH 7.4, 200 mL of HAase solution with pH 6.0, and 200 mL of HAase solution with pH 7.4 were added to the four beakers, respectively, and dialysis treatment was performed. The dialysate was taken at 0 h, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, and 3 h, and the cumulative release amount of the bacteriostatic component under different conditions was determined at a wavelength of 275 nm.

[0066] The cumulative release amount of the bacteriostatic component under different conditions is shown in Figure 1 Without HAase, only 10.8% and 14.0% of the bacteriostatic substance was released from the microcapsules in PBS with pH = 6.0 and pH = 7.4 within 3 h; in the HAase solution with pH = 6.0, only 19.1% of the bacteriostatic substance was released from the microcapsules within 3 h. Only in the HAase solution with pH = 7.4 was there a significant release of the bacteriostatic component, with a release rate of 72.3% within 3 h. Therefore, it can be seen that the release behavior of the bacteriostatic microcapsules is stimulated by both pH and HAase.

[0067] Example 5

[0068] To study the bacteriostatic performance of the bacteriostatic microcapsules on pathogenic bacteria, the bacteriostatic circle method was used to determine the inhibitory activity of Staphylococcus aureus and other pathogenic bacteria as indicator strains, according to GB 15979-2002 "Hygienic Standard for Disposable Hygienic Products" and GB / T 39101-2020 "Determination of Polypeptide Antimicrobial Activity by Inhibition Zone Method" with modifications. The indicator bacteria were inoculated into the designated culture medium from the frozen tube and incubated at 37°C for 18 h. The indicator bacteria were diluted to 1 x 105 CFU / mL of bacterial suspension with PBS phosphate buffer solution with pH = 7.4. The diluted indicator bacterial suspension was added to the designated culture medium at a volume fraction of 2%, and after thorough stirring, 20 mL was poured into a sterile petri dish. The petri dish was gently shaken to evenly distribute the culture medium, and after solidification, the Oxford cups were placed at equal intervals. 150 μL of the bacteriostatic component microcapsule mixture obtained in Example 1, i.e., the bacteriostatic component microcapsule solution, was slowly added to the Oxford cups. The sterile petri dish was removed from the 4°C refrigerator after 12 h of pre-diffusion and placed in a 37°C (indicator bacteria incubation temperature) incubator for constant upright incubation until the bacteriostatic circle was clear. The bacteriostatic circle diameter was measured using the bacteriostatic circle method, and each bacteriostatic circle was measured in three different directions, with the average value recorded. The results of the bacteriostatic performance are shown in Table 1.

[0069] Table 1

[0070] Strain Diameter of inhibition zone (mm) Escherichia coli 22.86±0.47 Staphylococcus aureus 21.09±0.32 Candida albicans 18.42±0.51 Gardnerella vaginalis 20.57±0.20

[0071] As shown in Table 1, the bacteriostatic component microcapsules prepared by the technical solution have obvious inhibitory effect on potential harmful bacteria (including Escherichia coli, Staphylococcus aureus, Candida albicans and Gardnerella vaginalis), and the diameters of the inhibition zones are all more than 15 mm.

[0072] Example 6

[0073] To verify the promoting effect of the bacteriostatic component microcapsules on common beneficial bacteria in the vaginal flora, the experiment is divided into an experimental group and a control group, and MRS liquid medium is used as the culture medium. The bacteriostatic component microcapsule solution is added to the experimental group, and the culture media of the two groups are sterilized at 121℃ for 15 min and then used. The experimental group and the control group are respectively inoculated with 1x10 7 CFU / mL of Lactobacillus crispatus and Lactobacillus gasseri, and cultured at 37℃ for 12h. The promoting effect of the bacteriostatic microcapsules on the beneficial Lactobacillus crispatus and Lactobacillus gasseri is evaluated by the number of viable bacteria. The calculation method is: promotion multiple = number of viable bacteria in the experimental group / number of viable bacteria in the control group.

[0074] The results show that the bacteriostatic component microcapsules in the application can promote the growth of common beneficial bacteria Lactobacillus crispatus and Lactobacillus gasseri in the vaginal flora, and the promotion of Lactobacillus crispatus is close to 3.9 times, and the promotion of Lactobacillus gasseri is close to 3.4 times.

[0075] Example 7

[0076] As Figure 2 shown, to study the cytotoxicity of the modified pure cotton non-woven fabric, the biological compatibility of the modified pure cotton non-woven fabric is evaluated by detecting the influence of the bacteriostatic component microcapsule mixture (i.e. bacteriostatic component microcapsule solution) prepared in Example 1 on the survival rate of L929 cells according to GB / T 16886.5-2017 “Biological Evaluation of Medical Devices Part 5: In Vitro Cytotoxicity Test”.

[0077] The influence of the bacteriostatic component microcapsule solution on the morphology of L929 cells is shown in Figure 2 As shown in Table 1, the bacteriostatic component microcapsules prepared by the technical solution have obvious inhibitory effect on potential harmful bacteria (including Escherichia coli, Staphylococcus aureus, Candida albicans and Gardnerella vaginalis), and the diameters of the inhibition zones are all more than 15 mm.

[0078] Although the present application has been particularly shown and described with respect to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details can be made therein without departing from the spirit and scope of the application as defined in the appended claims.

Claims

1. A high-softness, skin-friendly sanitary napkin characterized in that, The modified pure cotton non-woven fabric is obtained by impregnating pure cotton non-woven fabric in bacteriostatic component microcapsule mixed solution, rolling, and drying. The bacteriostatic component microcapsule mixed solution comprises the following raw materials: cis-9-unsaturated long-chain fatty acid, oregano essential oil, hyaluronic acid, polylactic acid, dichloromethane, polyvinyl alcohol, polyacrylic acid, 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide, N-hydroxysuccinimide, dopamine, ammonia water, and deionized water.

2. The highly flexible skin-friendly sanitary napkin according to claim 1, wherein The first composite layer dissolves when contacting weak alkaline menstrual blood.

3. The highly flexible skin-friendly sanitary napkin as claimed in claim 1, wherein, The second composite layer dissolves when contacting bacterial extracellular hydrolase.

4. The highly flexible skin-friendly sanitary napkin as claimed in claim 1, wherein, The first composite layer dissolves before the second composite layer.

5. The highly flexible skin-friendly sanitary napkin as claimed in claim 1, wherein, The bacteriostatic component microcapsule releases a mixture of cis-9-unsaturated long-chain fatty acid and oregano essential oil when simultaneously contacting weak alkaline menstrual blood and hyaluronidase secreted by bacteria.

6. A process for the preparation of a high softness skin friendly sanitary napkin characterized in that, The following preparation steps are included: S1, preparation of a composite bacteriostatic solution: uniformly mix cis-9-unsaturated long-chain fatty acid and oregano essential oil in a weight ratio of 1:1-3 to obtain a composite bacteriostatic solution; S2, preparation of bacteriostatic component microcapsule suspension: take 1-10 parts by weight of hyaluronic acid and 10-30 parts by weight of deionized water, add hyaluronic acid to deionized water and stir to dissolve to obtain a hyaluronic acid solution; take 1-10 parts by weight of polylactic acid and add it to the hyaluronic acid solution, stir to dissolve, form a mixed solution of hyaluronic acid modified polylactic acid, and then treat it by dialysis to obtain a dialysate; take 10-30 parts by weight of the composite bacteriostatic solution and 45-60 parts by weight of dichloromethane and add them to the dialysate to mix uniformly as an oil phase; take 10-30 parts by weight of polyvinyl alcohol and dissolve it in 100-300 parts by weight of deionized water as an aqueous phase, mix the oil phase and the aqueous phase uniformly, water bath for 1-3 h, then perform high-speed shearing treatment to obtain bacteriostatic component microcapsule suspension; S3, preparation of PD powder: dissolve 15-30 parts by weight of polyacrylic acid in 150-300 parts by weight of deionized water, add 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide and N-hydroxysuccinimide as catalysts, mix uniformly, ice water bath for 3-4 h, then add dopamine, mix uniformly, stir for 20-24 h, then perform dialysis treatment, freeze-drying to obtain PD powder; S4, preparation of bacteriostatic component microcapsules: the bacteriostatic component microcapsule suspension obtained in step S2 is dispersed in an ammonia buffer solution to obtain a first mixed solution; the PD powder obtained in step S3 is dissolved in deionized water to obtain a second mixed solution; the second mixed solution is slowly added to the first mixed solution while stirring to form polydopamine by dopamine self-polymerization, and the stirring is continued for 20-24 h; centrifugal treatment is performed to remove the supernatant, the precipitate is taken and washed with deionized water, and vacuum drying is performed to obtain bacteriostatic component microcapsules; S5, preparation of modified pure cotton non-woven fabric: the bacteriostatic component microcapsules obtained in step S4 are dissolved in water, the pH is adjusted to 6-6.5 to obtain a bacteriostatic component microcapsule mixture, and then the pure cotton non-woven fabric is immersed in the bacteriostatic component microcapsule mixture, rolled and dried to obtain a modified pure cotton non-woven fabric; S6, preparation of high-soft skin-friendly sanitary napkin: the modified pure cotton non-woven fabric is used as the surface layer of the sanitary napkin, and the sanitary napkin is compounded according to the structure of surface layer, flow guide layer, core body, and leakage-proof bottom film from top to bottom to obtain the high-soft skin-friendly sanitary napkin.

7. A process for the preparation of a highly soft and skin-friendly sanitary napkin as claimed in claim 6, wherein, The dialysis treatment is performed in a dialysis bag with a molecular weight cut-off of 3000-3500 Da for 4-8 h.

8. A process for the preparation of a highly soft and skin-friendly sanitary napkin as claimed in claim 6, wherein, The water bath reaction is performed in a magnetic stirring water bath at a water bath temperature of 40-60℃.

9. A process for the preparation of a highly soft and skin-friendly sanitary napkin as claimed in claim 6, wherein, The high-speed shearing treatment is performed in a high-speed shearing homogenizer at a speed of 10000-12000 rpm.

10. A process for the preparation of a highly soft and skin-friendly sanitary napkin as claimed in claim 6, wherein, The centrifugal treatment is performed in a centrifuge at a speed of 5000-6000 r / min for 5-10 min.

Images